{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:54Z","timestamp":1790007294778,"version":"4.0.1"},"reference-count":16,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Cord blood transplantation (CBT) is limited by delayed hematopoietic recovery leading to frequent use of double-unit grafts. This phase II study evaluated the safety of adding dilanubicel, a cryopreserved, cord blood (CB)\u2013derived, non\u2013human leukocyte antigen-matched expanded progenitor cell product generated from pooled donors to single-unit CBT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      Between March 2022 and July 2025, we enrolled 28 patients with hematologic malignancies in this single-center phase II trial. The infusion of a matched single CB unit was followed by a target dose of 800 \u00d7 10\n                      <jats:sup>6<\/jats:sup>\n                      CD34\n                      <jats:sup>+<\/jats:sup>\n                      cells of dilanubicel. All patients received a myeloablative conditioning regimen and graft-versus-host disease (GVHD) prophylaxis consisting of cyclosporine and mycophenolate mofetil.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The median age was 36 years (range, 10-63). Underlying diagnoses included acute leukemias (n = 25) and other hematologic malignancies (n = 3). All patients engrafted neutrophils (median, 18 days; range, 14-30) and platelets (median, 31 days; range, 26-43). Dilanubicel induced transient myelomonocytic recovery, peaking on day 7 and absent by day 14. An early lymphocyte expansion, derived exclusively from the CB graft, occurred by day 9 and peaked by day 11. No grade 3 to 4 acute or chronic GVHD was observed. At a median follow-up of 1.4 years, 27 patients remain alive and disease-free. When evaluated alongside a contemporaneous institutional cohort receiving standard single- or double-unit CBT, patients treated with dilanubicel demonstrated faster hematopoietic recovery and a markedly lower incidence of severe acute GVHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The addition of dilanubicel to single-unit CBT demonstrated a favorable safety profile, with no severe acute or chronic GVHD, and was associated with excellent clinical outcomes. These findings support further investigation of this strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02510","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:00:09Z","timestamp":1777320009000},"page":"1981-1991","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"first","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1966-949X","authenticated-orcid":false,"given":"Laura","family":"Roberts","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Azure","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-3162","authenticated-orcid":false,"given":"Lauren","family":"Martin","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-8719","authenticated-orcid":false,"given":"Francesco","family":"Mazziotta","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-9002","authenticated-orcid":false,"given":"Brandon","family":"Hadland","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-2801","authenticated-orcid":false,"given":"Colleen","family":"Delaney","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602074"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405584"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003371"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-092130"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285304"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.01.006"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694349"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30023-0"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2080"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.12.711"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015938"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18863"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.15.8639"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14294"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004462"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01931-7"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:49:05Z","timestamp":1784123345000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["10.1200\/JCO-25-02510"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02510","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2025-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}